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Cytotoxic T lymphocyte antigen-4 (CTLA-4), a membrane
bound inhibitory receptor whose expression is induced on
activated T cells, has been established as an important reg-
ulator of T cell responses and serves to maintain periph-
eral tolerance. Additionally, recent characterization of a
novel mechanism of extrinsic suppression mediated by the
soluble isoform of CTLA-4 (sCTLA-4) has served to
further establish the importance of CTLA-4 in maintain-
ing homeostasis of the immune system. Previously, we
have shown that selective blockade of sCTLA-4 in patients
with metastatic melanoma enhances immune responses
including increased antigen-specific proliferation of both
CD4+ and CD8+ T cells, compared with an isotype anti-
body control or pan CTLA-4 blockade. Selective blockade
also enhanced T cell effector cytokine responses, notably
IFN-g and IL-17. In this study, we demonstrate a protocol
for generating a regulatory T cell population, which is
characterised by the production of high levels of sCTLA-4.
Treatment of naïve human T cells with TGF-b2 together
with an anti-CD3 mAb/IL-2 T cell stimulus increased
their capacity to produce high levels of sCTLA-4, while
decreasing production of effector cytokines - IFN-g, IL-17
and IL-10. Furthermore, analysis of these sCTLA-4 produ-
cing T cells has shown that they express the T regulatory
cell transcription factor – FoxP3. Taken together, our data
show that TGF-b2 could serve as an attractive therapeutic
tool to alleviate symptoms of autoimmunity through the
induction of regulatory T cell populations that secrete
immunosuppressive sCTLA-4; while on the other hand,
neutralizing the effects of TGF-b2 could also prove benefi-
cial to patients with cancer.
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